AbbVie Inc. (NEO:ABBV)

Market Cap	483.44B
Revenue (ttm)	79.55B
Net Income (ttm)	5.08B
Shares Out	n/a
EPS (ttm)	2.86
PE Ratio	95.21
Forward PE	15.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,994
Average Volume	6,177
Open	27.73
Previous Close	26.81
Day's Range	27.55 - 28.08
52-Week Range	23.68 - 31.45
Beta	0.48
RSI	62.91
Earnings Date	Jul 25, 2025

About Ligand Pharmaceuticals

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.